{"id":"W2921797044","doi":"10.1016/s2213-2600(18)30500-9","title":"Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study","year":2019,"lang":"en","type":"article","venue":"The Lancet Respiratory Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":182,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Janssen Canada; Pfizer Canada; Bristol-Myers Squibb Canada; Merck Sharp and Dohme; AstraZeneca Canada; Genentech; Boehringer Ingelheim; MedImmune; Merck; AbbVie; Novartis; Roche; Eli Lilly and Company","keywords":"Medicine; Pembrolizumab; Internal medicine; Clinical endpoint; Adverse effect; Lung cancer; Oncology; Cohort; Cancer; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002740671,0.001362683,0.002422033,0.0003303517,0.0003932568,0.001465881,0.0008215182,0.001400927,0.002034396],"category_scores_gemma":[0.001195016,0.0004992647,0.002292477,0.0004290565,0.0007585511,0.00173343,0.0003438193,0.003552496,0.0006863395],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001022895,"about_ca_system_score_gemma":0.0009617305,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001091468,"about_ca_topic_score_gemma":0.002742302,"domain_scores_codex":[0.9994468,0.00022366,0.00002643561,0.0001111921,0.00006361211,0.0001282748],"domain_scores_gemma":[0.9992511,0.0002142094,0.0001988984,0.00005873794,0.00005382776,0.0002232329],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7503898,0.02465481,0.01146043,0.002484568,0.004776055,0.0002740378,0.0002929612,0.002833033,0.01991929,0.0002847978,0.006453316,0.1761768],"study_design_scores_gemma":[0.708914,0.2292814,0.0488358,0.0002015713,0.003143011,0.0003788932,0.0001601797,0.00173323,0.002079279,0.0003569228,0.004841739,0.00007411392],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9814723,0.01269918,0.0004474279,0.0008651917,0.0002290042,0.0007308093,0.001532984,0.00008506206,0.001938123],"genre_scores_gemma":[0.9820352,0.008509262,0.000964969,0.001857421,0.0002968545,0.000737703,0.003354435,0.00003358399,0.002210597],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002740671,"threshold_uncertainty_score":0.01449418,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03974779098585332,"score_gpt":0.3540708388786967,"score_spread":0.3143230478928434,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}